Literature DB >> 34652572

Perioperative management of antithrombotic therapy: a case-based narrative review.

Andrew Tiger Chen1, Matthew Patel1, James Demetrios Douketis2.   

Abstract

The periprocedural management of patients who are receiving vitamin K antagonists, direct oral anticoagulants and antiplatelet therapy is a common and challenging clinical scenario as the decision to interrupt or continue these medications is anchored on patient and procedure-related risks for bleeding and thrombosis. Adding to the complexity of clinical management is the fact that anticoagulants have varied pharmacokinetic and pharmacodynamic properties and indications for clinical use. In many minimal-bleed-risk procedures, anticoagulants can be safely continued, without interruption, whereas in cases where anticoagulants cannot be safely continued, the timing of interruption and resumption, as well as the need for heparin bridging requires consideration. Perioperative antithrombotic management scenarios occur most often in patients with atrial fibrillation, mechanical heart valves, coronary stents, and cerebrovascular disease as such patients are likely to be prescribed anticoagulant and/or antiplatelet therapy. The objective of this case-based narrative review is to provide a practical evidence-based approach to the perioperative management of patients on anticoagulation and antiplatelet therapy. Four clinical scenarios will be provided: (1) managing patients in whom anticoagulants can be continued; (2) perioperative management of direct oral anticoagulants; (3) management of patients on dual antiplatelet therapy; and (4) anticoagulant management for emergency or urgent surgery.
© 2021. Società Italiana di Medicina Interna (SIMI).

Entities:  

Keywords:  Anticoagulation; Direct oral anticoagulant; Heparin bridging; Perioperative management; Vitamin K antagonist; Warfarin

Mesh:

Substances:

Year:  2021        PMID: 34652572     DOI: 10.1007/s11739-021-02866-x

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  43 in total

1.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

Authors:  Manesh R Patel; Kenneth W Mahaffey; Jyotsna Garg; Guohua Pan; Daniel E Singer; Werner Hacke; Günter Breithardt; Jonathan L Halperin; Graeme J Hankey; Jonathan P Piccini; Richard C Becker; Christopher C Nessel; John F Paolini; Scott D Berkowitz; Keith A A Fox; Robert M Califf
Journal:  N Engl J Med       Date:  2011-08-10       Impact factor: 91.245

Review 2.  Perioperative management of anticoagulant and antiplatelet therapy.

Authors:  Alfonso Tafur; James Douketis
Journal:  Heart       Date:  2017-12-07       Impact factor: 5.994

3.  Apixaban versus warfarin in patients with atrial fibrillation.

Authors:  Christopher B Granger; John H Alexander; John J V McMurray; Renato D Lopes; Elaine M Hylek; Michael Hanna; Hussein R Al-Khalidi; Jack Ansell; Dan Atar; Alvaro Avezum; M Cecilia Bahit; Rafael Diaz; J Donald Easton; Justin A Ezekowitz; Greg Flaker; David Garcia; Margarida Geraldes; Bernard J Gersh; Sergey Golitsyn; Shinya Goto; Antonio G Hermosillo; Stefan H Hohnloser; John Horowitz; Puneet Mohan; Petr Jansky; Basil S Lewis; Jose Luis Lopez-Sendon; Prem Pais; Alexander Parkhomenko; Freek W A Verheugt; Jun Zhu; Lars Wallentin
Journal:  N Engl J Med       Date:  2011-08-27       Impact factor: 91.245

4.  Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation.

Authors:  James D Douketis; Alex C Spyropoulos; Scott Kaatz; Richard C Becker; Joseph A Caprini; Andrew S Dunn; David A Garcia; Alan Jacobson; Amir K Jaffer; David F Kong; Sam Schulman; Alexander G G Turpie; Vic Hasselblad; Thomas L Ortel
Journal:  N Engl J Med       Date:  2015-06-22       Impact factor: 91.245

5.  Scientific and Standardization Committee Communication: Guidance document on the periprocedural management of patients on chronic oral anticoagulant therapy: Recommendations for standardized reporting of procedural/surgical bleed risk and patient-specific thromboembolic risk.

Authors:  Alex C Spyropoulos; Karim Brohi; Joseph Caprini; Charles Marc Samama; Deborah Siegal; Alfonso Tafur; Peter Verhamme; James D Douketis
Journal:  J Thromb Haemost       Date:  2019-08-22       Impact factor: 5.824

6.  Dabigatran versus warfarin in patients with atrial fibrillation.

Authors:  Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

7.  Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT).

Authors:  A S Dunn; A C Spyropoulos; A G G Turpie
Journal:  J Thromb Haemost       Date:  2007-08-07       Impact factor: 5.824

8.  Edoxaban versus warfarin in patients with atrial fibrillation.

Authors:  Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245

9.  Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial.

Authors:  Michael J Kovacs; Philip S Wells; David R Anderson; Alejandro Lazo-Langner; Clive Kearon; Shannon M Bates; Mark Blostein; Susan R Kahn; Sam Schulman; Elham Sabri; Susan Solymoss; Tim Ramsay; Erik Yeo; Marc A Rodger
Journal:  BMJ       Date:  2021-06-09

10.  Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant.

Authors:  James D Douketis; Alex C Spyropoulos; Joanne Duncan; Marc Carrier; Gregoire Le Gal; Alfonso J Tafur; Thomas Vanassche; Peter Verhamme; Sudeep Shivakumar; Peter L Gross; Agnes Y Y Lee; Erik Yeo; Susan Solymoss; Jeannine Kassis; Geneviève Le Templier; Stephen Kowalski; Mark Blostein; Vinay Shah; Elizabeth MacKay; Cynthia Wu; Nathan P Clark; Shannon M Bates; Frederick A Spencer; Eleni Arnaoutoglou; Michiel Coppens; Donald M Arnold; Joseph A Caprini; Na Li; Karen A Moffat; Summer Syed; Sam Schulman
Journal:  JAMA Intern Med       Date:  2019-11-01       Impact factor: 21.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.